Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2007

View Archived Issues

Antigen Express and University of Rochester to collaborate on avian influenza vaccine

NCI initiates glycan-based biomarker R&D program for cancer detection

Nuvelo enrolls patients in phase III trial of 10 mg alfimeprase for CO

EKR Therapeutics acquires rights to DepoDur for treatment of postoperative pain

New antidiabetic agents divulged in recent patent literature

Gene Logic enters new drug repositioning and development agreements

Positive results for CollaGenex's phase II study of Col-118 for erythema

Recent GSK and sanofi-aventis patents divulge novel analgesic agents

Novel agents for treating HCV infection disclosed in recent Kurume University patent

New data on lacosamide for the treatment of pain

Neuroprotective activity of Cerebrolysin in transgenic mouse model of Alzheimer's

Genentech resubmits sBLA to FDA for Avastin combination therapy

ImClone's phase II study of IMC-1121B for renal cancer opens for enrollment

Implicit begins phase IIa trial of intranasal oglufanide disodium for HCV

Neurochem reports top-line results from phase III trial of tramiprosate

ReGen reports results of phase IIa study of antidormancy effects of zolpidem

Antiatherosclerotic mechanism of the antioxidants AGI-1095 and AGI-1067 elucidated

Bioequivalence achieved with pioglitazone, glimepiride co-therapy and combination tablets

Study points to CRF receptors as target for interstitial cystitis and overactive bladder

Silodosin improves storage and voiding dysfunction in benign prostatic hyperplasia

Experimental evidence points to besipirdine efficacy in urinary incontinence

D-4F attenuates cardiac allograft vasculopathy in a murine model

2-Acetamidoindoles identified at ICAgen as potent, selective KCNQ channel openers

Triazine-based antiinflammatory compounds in development at ProMetic

Merck discusses SAR data for series of selective MC4 receptor agonists at ACS

Potent, selective, orally available H3 antagonists prepared by Abbott neuroscience team

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...